Salute e Benessere

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S…

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive, relentless disease TOKYO and CAMBRIDGE, Mass., Sept.02, 2025(GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that...
Nasdaq GlobeNewswire
03/09/2025

Clostridioides difficile Infection Market Forecasts by DelveInsight Signal…

Clostridioides difficile Infection Market Summary Clostridioides difficile Infection Market Summary Discover the CDI new treatment @ New Treatments for CDI Key Factors Driving the Growth of theClostridioides difficileInfection (CDI) Market Aging CDI population and at-risk groups Advanced age, frequent hospital exposure, comorbidities, and immunosuppression are major risk factors for CDI. Global population aging and increased hospital/long-term care use concentrate...
PR Newswire
02/09/2025

3-minute EEG Test Reliably Detects Memory Impairment, Enabling Earlier…

The study found that the three-minute, non-invasive Fastball EEG test can reliably identify early memory impairment in individuals with Mild Cognitive Impairment (MCI), a condition often preceding Alzheimer's disease dementia. This ground-breaking finding builds on previous research and, for the first time, validates the technology's ability to deliver reliable results in a real-world setting, with clinical staff visiting patients in their homes. Cumulus is developing AccelADx, a scalable…
PR Newswire
02/09/2025

SprintRay Acquires EnvisionTEC Dental Product Portfolio, Expanding Commitment to…

"SprintRay's acquisition of EnvisionTEC's dental portfolio ensures existing customers continue to have the tools and support they rely on, while also strengthening our position in dental labs," said Amir Mansouri, PhD, SprintRay Co-founder and CEO. "Our mission to transform dentistry through accessible, reliable 3D printing technology hasn't wavered. This strategic move reinforces that commitment." "SprintRay's acquisition of EnvisionTEC's dental portfolio ensures…
PR Newswire
02/09/2025

/DISREGARD RELEASE: SprintRay, Inc./

PR Newswire
02/09/2025

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of…

Morgan Stanley 23rd Annual Global Healthcare Conference Tuesday, September 9, 2025, at 8:30 A.M. ETBofA Global Healthcare Conference 2025 (London) Wednesday, September 24, 2025, at 9:00 A.M. British Summer Time (4.00 A.M. Eastern Time) To access a live webcast of the presentation, visit Teva’s Investor Relations website athttps://ir.tevapharm.com/Events-and-Presentations.An archived version of the webcast will be available within 24 hours after the end of the live discussion...
Nasdaq GlobeNewswire
02/09/2025

Nyxoah Announces Upcoming Investor Events

Nyxoah Announces Upcoming Investor EventsMont-Saint-Guibert, Belgium – September 2, 2025, 10:30pm CET / 4:30PM ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the following events during September: 2025 Wells Fargo Healthcare ConferenceSeptember 3 rd– Boston, MA Cantor Global Healthcare...
Nasdaq GlobeNewswire
02/09/2025

Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment…

PARIS and CAMBRIDGE, Mass., Sept.02, 2025(GLOBE NEWSWIRE) --NANOBIOTIX(Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in a fireside chat at following conference: H.C. Wainwright 27th Annual Global Investment ConferenceDate: Tuesday, September 9th, 2025...
Nasdaq GlobeNewswire
02/09/2025

SprintRay Acquires EnvisionTEC Dental Product Portfolio, Expanding Commitment to…

"SprintRay's acquisition of EnvisionTEC's dental portfolio ensures existing customers continue to have the tools and support they rely on, while expanding our leadership across both chairside practices and dental labs," said Amir Mansouri, PhD, SprintRay Co-founder and CEO. "Our mission to transform dentistry through accessible, reliable 3D printing hasn't wavered. This acquisition reinforces that commitment." "SprintRay's acquisition of EnvisionTEC's dental portfolio…
PR Newswire
02/09/2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 2025

Aggregated presentation by day and by marketStatement of transactions in own shares from August 25 thto August 29 th2025Name of the issuerIdentity code of the issuer(Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1125/08/2025FR0010259150 300116,2AQEU...
Nasdaq GlobeNewswire
02/09/2025

Quasar Medical Strengthens Global CDMO Platform with Acquisition of Nordson…

Quasar's evolution into a fully integrated Contract Development and Manufacturing Organization (CDMO) marks a transformative step, offering customers concept-to-commercialization solutions worldwide. The company is expanding its workforce by nearly 200 employees, including expert development engineers and technicians, creating new opportunities for advancement. Quasar's evolution into a fully integrated Contract Development and Manufacturing Organization (CDMO) marks a transformative step,...
PR Newswire
02/09/2025

Vaccines Market worth $63.66 billion in 2030 with 4.8% CAGR | MarketsandMarkets™

Browse in-depth TOC on "Vaccines Market" Browse in-depth TOC on "Vaccines Market" 350 - Tables 70 - Figures 400 - Pages By disease indication,the vaccines market is divided into pneumococcal disease, influenza, combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, varicella, hepatitis, DTP, polio, RSV, and other disease indications (cancer, COVID-19, dengue, tuberculosis, typhoid, Japanese encephalitis, rabies, yellow fever, and allergies)...
PR Newswire
02/09/2025

Gifthealth + Occam Health: Transforming Patient Access at Scale

Gifthealth is the nation's largest direct-to-patient partner for manufacturers and a pioneer in digital-first brand experiences. Integrating with Occam's high-touch, personalized model positions the combined company to cut through today's fragmented, friction-filled patient journey. Gifthealth is the nation's largest direct-to-patient partner for manufacturers and a pioneer in digital-first brand experiences. Integrating with Occam's high-touch, personalized model positions the combined…
PR Newswire
02/09/2025

Minimally Invasive Surgery Market worth US$199.30 billion by 2030 with 16.1%…

Browse in-depth TOC on "Minimally Invasive Surgery Market" Browse in-depth TOC on "Minimally Invasive Surgery Market" 459 - Tables60 - Figures389 - Pages By product,the global minimally invasive surgery market is segmented into surgical devices, imaging and visualization systems, electrosurgical devices, endoscopy devices, and medical robotics. Among these, in 2024, the surgical devices segment held the largest market share. This is because of its crucial role in all...
PR Newswire
02/09/2025

Bioretec Appoints Jordy Winters as Vice President of OUS Sales to Accelerate…

Sarah van Hellenberg Hubar-Fisher, CEO of Bioretec, states: "We are delighted to welcome Jordy Winters to our executive team. With nearly two decades of proven excellence in global orthopedic commercial leadership, his expertise and international perspective will be instrumental as we continue to expand Bioretec's impact outside the U.S." Sarah van Hellenberg Hubar-Fisher, CEO of Bioretec, states:"We are delighted to welcomeJordy Wintersto our executive team. With nearly two…
PR Newswire
02/09/2025

Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands

VANCOUVER, BC, Sept. 2, 2025 /PRNewswire/ -- Cancer innovation is reaching new heights as the FDA approved breakthrough therapies for aggressive malignancies, including Modeyso for deadly brain tumors, while breakthrough designations accelerate for next-generation therapies targeting previously resistant cancers. This regulatory momentum builds upon a wave of July breakthrough designations and regulatory milestones spanning multiple cancer types. The expanding regulatory support is generating…
PR Newswire
02/09/2025

Quotient Sciences and CPI to Accelerate RNA Drug Development with Joint Venture

"This is a pivotal moment for RNA drug development," said Thierry Van Nieuwenhove, CEO at Quotient Sciences. "The combined innovation and deep technical expertise of Quotient and CPI will enable developers to benefit from a vastly accelerated supply chain, with clinical batches going from plasmid to clinical dose in as little as two months. This offers a highly streamlined pathway to early-phase clinical trials for mRNA drug candidates". "This is a pivotal moment for RNA…
PR Newswire
02/09/2025

Seegene and Springer Nature Open Applications for 2025-2026 Nature Awards MDx…

Now in its third cycle since 2023, the program invites researchers worldwide to submit product development ideas and clinical research projects. Based on unmet clinical needs, applicants can propose up to 18 resistance genes associated with urinary tract infections as assay targets. Final awardees will receive up to USD 600,000 in research funding, along with access to Seegene's syndromic PCR assays, consumables, instruments, and software to support the development of innovative diagnostics. ...
PR Newswire
02/09/2025

EQT Foundation opens applications for breakthrough research grant in rare…

The program seeks research at the intersection of deeptech innovation and clinical application, with a focus on: The program seeks research at the intersection of deeptech innovation and clinical application, with a focus on: Cilia Holmes Indahl, CEO, EQT Foundation, comments: "Rare diseases often go unseen and unheard, leaving millions, many of them children, without effective treatments or timely diagnoses. Through this fast-track grant program, we're not just funding research, we're...
PR Newswire
02/09/2025

Menarini Group's Obicetrapib and Obicetrapib/Ezetimibe Marketing Authorisation…

The Phase 3 BROOKLYN (NCT05425745), BROADWAY (NCT05142722) and TANDEM (NCT06005597) studies evaluated obicetrapib and obicetrapib/ezetimibe on top of maximally tolerated lipid lowering therapies compared to placebo in patients unable to reach low-density lipoprotein cholesterol (LDL-C) goals with the maximum tolerated dose of a statin or in patients who are statin-intolerant, or for whom a statin is contraindicated. BROADWAY and TANDEM were published on NEJM and The Lancet. The Phase 3 PREVAIL…
PR Newswire
02/09/2025

Coag-Sense® PT/INR Monitoring System Approved for Patient Self-Testing in Europe

®PT/INR Monitoring System for patient self-testing in Europe.The approval was granted in the form of an EU Technical Documentation Assessment Certificate under Regulation (EU) 2017/746 (IVDR) for in vitro diagnostic medical devices (Class C). The device is intended for use by properly selected and trained patients, or their caregivers, under the supervision of a treating physician to monitor oral anticoagulation therapy in patients receiving warfarin-type anticoagulants.“CoaguSense...
Nasdaq GlobeNewswire
02/09/2025

ZEISS showcases expansion of ophthalmic care options creating industry-leading…

"ZEISS continues to introduce advanced optical and digital innovation to meet the expanding needs of Europe's leading refractive and cataract surgeons," says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. "From major industry milestones to new digital workflow solutions, our industry leadership shines bright, setting new standards for ophthalmic care." "ZEISS continues to introduce advanced optical and digital innovation…
PR Newswire
02/09/2025

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy…

– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies –– Substantial increase in seizure-free days and continuous improvements in quality of life demonstrated in patients already taking standard of care anti-seizure medicines –– Zorevunersen generally well tolerated across all studies –– Data support pivotal Phase 3 EMPEROR study now underway –...
Nasdaq GlobeNewswire
02/09/2025

Trading by management and close relations of management

Please read the announcement in PDF Attachment 2025_43_Trading_By_Management
Nasdaq GlobeNewswire
02/09/2025
Altri  Comunicati